Abstract Number: PB0273
Meeting: ISTH 2021 Congress
Background: Inflammatory response plays a key role in Coronavirus Disease 2019 (COVID-19) as it has been shown that the resulting cytokine storm increases its severity.
Aims: This study aimed to investigate the role of procalcitonin (PCT) on patients afflicted with severe forms of COVID-19.
Methods: This study was a retrospective cohort study. For the purpose of this research, 150 severe cases of COVID-19 who were hospitalized in ICU were investigated. The required data about patients’ demographic information, clinical and laboratory findings, and their PCT level were collected upon their admission to the hospital and from the disease outcome data. Then the needed statistical analyses were performed on them.
Results: From the 150 patients who entered the study, 77 cases were discharged from the hospital alive. The mean age of the patients was 60.92±16.33 years and 51.3% of them were male. The mean PCT level of the deceased cases was 2.43±3.40 while that of the surviving cases was 0.73±1.28, which represented a statistically significant difference between the two groups in this regard. Results indicated that PCT can be used as one of the independent factors for predicting mortality.
Conclusions: Serum PCT level can predict mortality and disease outcome in patients suffering from severe forms of COVID-19.
To cite this abstract in AMA style:Zakeri A, Matin S, Rezaei Ghalechi E. Is Procalcitonin Involved on the Severity of COVID-19? [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/is-procalcitonin-involved-on-the-severity-of-covid-19/. Accessed September 29, 2023.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/is-procalcitonin-involved-on-the-severity-of-covid-19/